Oslo  (Norway), 2 September 2020 - Exercise of employee share options, mandatory
notification  of  trade  and  resolution  to  increase  the share capital in PCI
Biotech Holding ASA (the "Company").

1.   Options exercised and mandatory notification of trade on 2 September 2020
Participants  in the  Company's share  option program  have on 2 September 2020
exercised  a total  number of  60,500 share options,  out of  these 26,000 share
options  were exercised at  a strike price  of NOK 7.84 and 34,500 share options
were exercised at a strike price of NOK 3.26, corresponding to a total number of
60,500 shares.  All of the  exercised share options  were about to expire unless
exercised.

Out  of the  total number  of exercised  share options, 54,500 share options are
exercised by the following primary insiders:

Primary  insider  Per  Walday  (CEO)  has  on 2 September 2020 exercised a total
number  of 9,000 share options at a strike  price of NOK 3.26. The share options
were  granted  to  Walday  in  November  2015 and  now  about  to  expire unless
exercised.  Subsequent to the exercise he has sold 4,600 shares in the market at
an  average price  of NOK  45.6 per share  in order  to finance the cash and tax
impact  of the transaction. After the  transaction Walday hold 72,700 shares and
155,000 share options in the Company.

Primary  insider Ronny Skuggedal (CFO) has on 2 September 2020 exercised a total
number  of 20,000 share options at a strike price of NOK 7.84 and a total number
of  6,000 share options at  a strike price  of NOK 3.26. The  share options were
granted  to Skuggedal  in April  2015 and November  2015 and now about to expire
unless  exercised. Subsequent to  the exercise he  has sold 14,000 shares in the
market  at an average price  of NOK 45.6 per share  in order to finance the cash
and  tax impact of the transaction. After the transaction Skuggedal hold 55,000
shares and 90,000 share options in the Company.

Primary insider Kristin Eivindvik (PD) has on 2 September 2020 exercised a total
number  of 6,000 share options at a strike  price of NOK 7.84 and a total number
of  7,500 share options at  a strike price  of NOK 3.26. The  share options were
granted  to Eivindvik  in April  2015 and November  2015 and now about to expire
unless  exercised. Subsequent to  the exercise she  has sold 7,100 shares in the
market  at an average price  of NOK 45.6 per share  in order to finance the cash
and  tax impact of the transaction. After the transaction Eivindvik hold 25,200
shares and 60,000 share options in the Company.

Primary insider Anders Høgset (CSO) has on 2 September 2020, as a participant in
the  Company's share  option program,  exercised a  total number  of 6,000 share
options  at a strike price of NOK 3.26. The share options were granted to Høgset
in  November 2015 and  now about  to expire  unless exercised. Subsequent to the
exercise he has sold 4,500 shares in the market at an average price of NOK 45.6
per  share. After  the transaction  Høgset hold  64,800 shares and 100,000 share
options in the Company.

This  announcement also represents  a mandatory notification  of trade, which is
submitted by the Company on behalf of the primary insiders.

2.   Resolution to increase the share capital
Following the exercise of share options on 2 September 2020, the Company's Board
of  Directors,  pursuant  to  an  authorisation  granted by the Company's Annual
General  Meeting on  27 May 2020, have  decided to  increase the Company's share
capital  with NOK 181,500 by issuing 60,500 new  shares, each share of par value
NOK 3.00. Subsequent to the transaction, the Company's share capital will be NOK
111,979,170 divided  into 37,326,390 shares,  each with  a nominal  value of NOK
3.00 and  each giving  one vote  at the  Company's general  meeting. The capital
increase will result in gross proceeds of NOK 316,310.

Contact information:
Per Walday, CEO

pw@pcibiotech.no

Mobile: +47 917 93 429



This information is subject to the disclosure requirements pursuant to section
4-12 and 5-12 of the Norwegian Securities Trading Act.